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1. Introduction
While primary malignant brain tumors account for only 2% of all adult cancers, these neo‐
plasms cause a disproportionate rate of cancer-related disability and death. The five-year
survival rates for brain tumors are the third lowest among all types of cancer, after pancreas
and lung ones, respectively.
High-grade gliomas (glioblastoma multiforme [GBM] and anaplastic astrocytoma [AA])
comprise the most common types of primary central nervous system (CNS) tumors and have
a combined incidence of 5-8/100,000 population. The median survival of patients with
malignant gliomas treated conservatively is 14 weeks; by surgical resection alone, 20 weeks;
by surgery and radiation, 36 weeks; by the addition of chemotherapy, 40-50 weeks [1].
The oncogenesis of gliomas, in particular high-grade gliomas (HGGs), the most frequent
primary malignant brain tumors in adults, is driven by several biological processes and genetic
alterations, involved in the transformation of a normal cell into a neoplastic one [2, 3].
Classically this step-by-step evolution from normal cells to early-stage tumors, to aggressive
cancer is found in cases of “secondary” multiforme glioblastoma (GBM), derived from a lower-
grade glioma, whereas some glioblastomas occur directly without previous evidence of a
lower-grade tumor. This last subset of tumors are classified as “primary” or “de novo” GBM
[4]. A relatively novel feature of GBM, so as of many other types of malignant tumors, is the
presence inside the gross of tumors of a particular kind of tumor cells, GBM stem cells. These
cells could represent the trigger and the maintenance of gliomagenesis.
© 2013 Raudino et al.; licensee InTech. This is an open access article distributed under the terms of the
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The majority of GBM cases (>90%) are primary GBM, involving mainly the elderly and
genetically characterized by loss of eterozygosity (LOH) 10q [70% of cases), EGFR amplifica‐
tion [36%), p16INK4a deletion [31%) and PTEN mutations [25%). Secondary GBMs [5% of all
cases of sporadic GBM) manifest in younger patients and are characterized often by TP53
mutations, the most frequent and detectable genetic alteration, already present at stage of low-
grade astrocytomas, in 60% of cases. LOH 10q [10q25-qter) is the most frequent [70%) genetic
alteration in both primary and secondary GBMs [5].
Gliomagenesis is driven by several biological processes and genetic alterations, involved in
the transformation of a normal cell into a neoplastic one [2, 3].
One of the most fashinating and futurible therapeutic strategy against gliomas is represented
by antisense therapy to block selectively glioma cells, trying to revert gliomagenetic molecular
pathways towards the wild-type status. This aim could be reached through antisense mole‐
cules, delivered inside the brain and in particular inside tumoral cells, able to penetrate into
glioma cells nucleus and to integrate with their genome to silence some specific genic functions.
Among antisense molecules there are antisense oligonucleotides, ribozymes and RNA
interference (iRNA). The specificity of hybridization makes antisense method an interesting
strategy to selectively modulate the expression of genes involved in tumorigenesis. Glial
tumors seem to be able to create a favorable environment for the invasion of glioma cells in
cerebral parenchyma when they combine with the extracellular matrix via cell surface
receptors. In this review we will focus on the different antisense approaches and on the
mechanisms of action of each kind of antisense molecule and relative strategy in human
gliomas therapy.
Among dysregulated molecular pathways, into brain tumor cells, there are activated growth
factors signaling pathways, marked angiogenesis, downregulation of apoptotic genes and
upregulation of antiapoptotic genes.
Gliomagenesis is driven by several biological events, such as activated growth factor receptor
signaling pathways, downregulation of many apoptotic mechanisms and unbalance among
proangiogenic and antiangiogenic factors. This last aspect is very crucial in glioma progression,
because of prominent angiogenesis is a cardinal feature of malignant gliomas [2]. Several
growth factor receptors, such epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDRGF), C-Kit, vascular endhotelial growth factor receptor (VEGFR)
and other growth factors receptors, are overexpressed, amplified and/or mutaded in gliomas.
Features of glioma cells are the loss of tumor suppressor genes, which are critical for cell
growth, differentiation and function. These genes are TP53, the retinoblastoma (Rb) gene, the
inhibitor of cyclin-dependent kinase 4a (INK4a) gene and the phosphatase and tensin homolog
(PTEN) gene [6].
On the basis of this high importance of gene expression disregulation inside cancer cell
genome, the modulation of gene expression at more levels, such as DNA, mRNA, proteins and
transduction signal pathways, may be the most effective modality to downregulate or silence
some specific genic functions pathologically upregulated or introduce genes, downregulated
or deleted selectively into neoplastic cells. Therapeutic genes (Transgenes) can lead to
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generation of anticancer drugs within the tumor (pro-drug activation), increase of selective
intratumoral drug levels without increasing systemic toxicity, protection of hematopoietic cells
from drug damage by inducing drug resistance and delivery of secreted fusion proteins which
combine a targeting ligand and a toxin/enzyme, sensitization of tumors to radiations, that in
turn can be used to induce expression of transgenes via radiation-activated promoters [7].
(Ohgaki and Kleihues. AJP May 2007, Vol. 170, No. 5)
Figure 1. De novo vs Secondary GBM genetic pathways
Progression from low-grade to high-grade astrocytomas involve inactivating mutations of
tumor-suppressor gene TP53 and elevated expression of platelet-derived growth factor
(PDGF) ligands and receptors, accumulation of genetic alteration of retinoblastoma-associated
cell-cycle regulatory pathways, including deletion or mutations of cyclin-dependent kinase
inhibitor p16INK4A/(CDKN2A) or the retinoblastoma susceptibility locus 1 (pRB1), as well as
amplification or over-expression of cyclin-dependent kinase 4 (CDK4) and human double
minute 2 (HDM2). Evolution to secondary GBM is associated with deletion of chromosome
10, which includes tumor-suppressor phosphatase and tensin homolog (PTEN). The hyper‐
methilatyion in the promoter region and successive mutation of p16 is evident in HGGs
progression. Additionally BcI2-like 12 increased expression (BcI2L12) inhibits apoptosis [8].
The astrocyte elevated gene-1 (AEG-1) is over-expressed in the majority of HGGs and stimu‐
lates cellular transformation and invasion together with the Ha-ras family of retrovirus-
associated DNA sequences (RAS). Furthermore, oncogenic Ha-ras induces AEG-1 expression
by modulating the phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway and contrib‐
utes to the growth of HGGs. Mitogenetic signals activate a molecular cascade known as ras-
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mitogen activated protein kinase (Ras/MAPK). MAPK inhibits the Rb gene, activates the
transcriptional factor E2F and cells enter the S phase. The INK4a gene influences the Rb
pathway by activating three cyclin kinase inhibitors: p15, p16, and p19.The final result is the
blockage of cyclin-dependent kinase 2, 4 and 6, triggering cell-cycle progression by inhibiting
pRb. Through the new technique of genome-wide sequencing and survey of gene copy
number, have been discovered novel amplicons linked to glioma progression. Table 1
summarizes the main genes involved in gliomagenesis (Tab. 1).
Gene Chromosome Molecular alteration Effect of the molecular
alteration
Histotype (WHO
Grade)
TP53 Cr17p13.1 Mutations Cell cycle control loss,
proliferation
Astrocytoma and
oligodendroglioma
(Grade II) – precocious
mutation in secondary
GBM
PDGF-A
PDGFR-α
Cr4q11-q12 Overexpressio/amplification Proliferation/invasion Astrocytoma and
oligodendroglioma
(Grade II-III)
Unknown
tumor
suppressor
genes
1p, 19q, 4q, 9p
and 11p loss
Loss of Heterozygosity Proliferation, invasiveness,
angiogenesis
Astrocytoma and
oligodendroglioma
(Grade II-III)
Unknown
tumor
suppressor
genes
Cr22q Deletion Proliferation Astrocytoma and
oligodendroglioma
(Grade II)
Rb 1 Cr13q14.2 Mutations/deletion Cell cycle control loss,
proliferation
Astrocytoma and
oligodendroglioma
(Grade II-III)
P16 Cr9p CDKN2/p16 deletion Cell cycle control loss,
proliferation
Astrocytoma and
oligodendroglioma
(Grade II-III)
PTEN Cr10q23 LOH Regulation Akt/PKB
signaling pathway loss;
proliferation and tumor
growth; invasiveness,
angiogenesis
Astrocytoma and
oligodendroglioma
(Grade III-IV)
BAX Cr19q24 LOH Pro-apoptotic action loss,
proliferation
Astrocytoma and
oligodendroglioma
(Grade II-III)
EGFR (c-erb-2) Cr7p11-p12 Amplification/overexpression Cell transformation and
proliferation
De novo GBM
MDM2 Cr12q14.3-q15 Overexpression Cell cycle control loss and
proliferation
De novo GBM
Table 1. Main genetic alteration in human gliomas
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Gliomagenesis can develop through two different ways, resulting in evolution of a cluster
genic alteration directly from normal astrocyte to GBM or of a step by step different kinds of
mutations of various genes passing gradually from normal astrocyte to low-grade glioma, to
high-grade glioma, to GBM.
Primary GBM shows amplification of the epidermal growth factor receptor (EGFR), deletion or
mutation of homozygous cyclin-dependent kinase (CDK) inhibitor p16INK4A /(CDKN2A), alter‐
ations in tumor suppressor PTEN on chromosome 10, and deletion in the INK4a gene with loss
of p14 and p16 [6, 9]. In table 2 we, also, report the principal familial genetic syndromes associat‐
ed with HGGs (Tab. 2). In the total amount of GBM, the total prevalence rate concern for the 95%
cases of sporadic GBM, and only for the 5% (not more) cases of syndromic familiar cancer.
Syndrome Involved gene Chromosomal
location
Protein function Effect of
molecular
alteration
Associated tumors
Turcot
[Variant form of
hereditary non-
polyposis colorectal
cancer (HNPCC) or
familial adenomatous
polyposis
APC
MLH1
PMS2 (mismatch
repair genes)
(Autosomal
dominant)
5q21
3p21.3
7p22
Signal transduction,
DNA mismatch
repair
Hyperplasia,
invasiveness and
metastasis
Colorectal polyposis
and primary brain
tumors
APC mutations are
commonly
associated with
medulloblastoma;
mismatch repair
mutations are
associated with
glioblastoma
Gardner
[Familial adenomatous
polyposis, with
intestinal polyposis,
desmoids, osteomas,
epidermoid cysts]
APC
RAS
DCC
TP53
(Autosomal
dominant)
5q21
12
18
17p13.1
Signal transduction,
proliferation, cell
and cell-to-matrix
adhesion
Hyperplasia,
invasiveness and
metastasis
Colonrectal, small
bowel, pancreatic,
stomach, bile duct,
papillary thyroid,
hepatoblastoma,
Brain tumors,
adrenal gland
cancer
Li-Fraumeny TP53
(Autosomal
dominant)
17p13.1 Transcription
factor, apoptosis
regulator
Abnormal
protein/gain of
function
Osteosarcomas,
soft-tissue sarcomas,
premenopausal
breast, adrenal
cortical, glioma,
primitive
neuroectodermal
tumor, leukemias
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Syndrome Involved gene Chromosomal
location
Protein function Effect of
molecular
alteration
Associated tumors
Von Recklinghausen
Neurofibromatosis
Type 1 (NF 1)
NF1
(neurofibromin)
(Autosomal
dominant)
17q11.2 GTPase activating
protein, negative
regulation of
p21ras
Proliferation Bilateral acoustic,
meningioma, esp.
multiple; piloid
astrocytoma, mid-
line glioma, diffuse
glioma,
intramedullary
astrocytoma, spinal
cord ependymoma
Neurofibromatosis
Type 2 (NF 2)
NF 2 22q12.2 Cytoskeletal-cell
membrane link
Proliferation Vestibular
schwannoma,
peripheral
schwannoma,
meningioma, spinal
ependymoma,
astrocytoma, glial
hamartoma
Tuberous sclerosis TSC1
TSC2
(Autosomal
dominant)
9q34
16p13
Not known GTPase
activating protein
Cell growth and
cell division
control loss,
proliferation
Subependymal giant
cell astrocytoma,
cortical tubers,
cutaneous
angiofibroma, peau
chagrin, cardiac
rhabdomyoma,
adenomatous
polyps of the small
intestine, cysts of
the lung and kidney
Retinoblastoma RB1
(Autosomal
recessive)
13q14 Regulator of
transcription
factors
Proliferation Retinoblastoma,
pineoblastoma,
glioma,
osteosarcoma
Multiple hamartoma
(Cowden Disease)
APC
hMLH1
hMSH2
PMS2
PTEN
(Autosomal
dominant)
5q21
3p21.3
2p22-21
7p22
10q23.3
Signal transduction,
DNA mismatch
repair
Hyperplasia;
proliferation,
apoptotic cell
death loss,
invasiveness and
metastasis
Dysplastic cerebellar
gangliocytoma,
hamartomas (skin,
breast, thyroid,
colon, intestines,
mouth)
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Syndrome Involved gene Chromosomal
location
Protein function Effect of
molecular
alteration
Associated tumors
Gorlin PTCH1
PTCH2
(Autosomal
dominant)
9q22.3-q31
1p32
Transmembrane
receptor
Proliferation Medulloblastoma,
meningioma,
astrocytoma,
multiple basal cell
carcinomas, palmar
and plantar pits
Table 2. Principal familial genetic syndromes associated with human gliomas
2. Glioma invasion
Glioma cells invasion consist of an active translocation of glioma cells through host cellular
and extracellular matrix barriers [10].
Three steps are fundamental in the phenomenon of glioma invasion: a) adhesion of glioma
cells to proteins of the surrounding extracellular matrix (ECM) mediated by cell adhesion
receptors; b) degradation of ECM components by proteases secretion by glioma cells; c)
migration of glioma cells into the newly created space through the ECM.
ECM is composed of proteoglycans, glycoproteins, collagens and also contains fibronectin,
laminin, tenascin, hyaluronic acid, vitronectin. In recent years the glioma invasion has also
been interpreted by numerous authors in terms of interaction between neoplastic cells and
ECM [11].
Critical factors include the synthesis and deposition of ECM components by glioma and
mesenchymal cells, the release of ECM-degrading activities for remodeling interstitial spaces,
the presence of adhesion molecules (matrix receptors on glioma cell surfaces that specifically
recognize and adhere to ECM components) and the effects of cell-matrix interactions on the
behavior of glioma cells. ECM modification aids the loss of contact inhibition allowing tumor
cells to freely migrate and invade the surrounding tissues. Changes in these ECM components
are felt to modulate brain tumor growth, proliferation and invasion, although specific
interactions and exact mechanisms are unknown.
Integrins, a class of adhesion molecules, play a major role in glioma cell-matrix adhesion. Integ‐
rins regulate many aspects of the cell behavior including survival, proliferation, migration and
differentiation. They act with a physical trans-membrane link between the ECM and the cytos‐
keleton and with a bi-directional signal across the cell membrane. Integrins of the β1 and αν
classes are expressed on different cell types, including neurons, glial cells, meningeal and endo‐
thelial cells. β2 integrins are specifically expressed by leukocytes and they are found on micro‐
glia and on infiltrating leukocytes within the CNS. Down-regulation of β1 expression in
intracerebrally transplanted glioma cells in vivo by placing β1 antisense sequences under an in‐
ducible, tetracycline-responsive promoter markedly inhibited diffuse brain invasion [13-17].
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Down-regulated β1 integrin protein levels in vivo probably affect interactions of glioma cells
with ECM components, leading to reduced migration along vascular basement membranes.
Figure 2.
The proteolytic degradation of the basement membrane (BM) is mediated by proteases, such as
the matrix metalloproteases (MMPs), secreted by tumor and stromal cells [11, 12]. MMPs are se‐
creted as proenzymes and are activated by proteolytic cleavage of their amino-terminal domain.
MMPs play an important role in human brain tumor invasion, probably due to an imbalance be‐
tween the production of MMPs and tissue inhibitor of metalloproteases-1 (TIMP-1) by the tumor
cells. Among these molecules, MMP-1 is the crucial enzyme able to initiate breakdown of the in‐
terstitial collagens, collagen type 1, collagen type 2 and collagen type 3; in this way it activates the
other MMPs which allow the glioma cells to infiltrate normal brain tissue.
3. Angiogenesis
The formation of new blood vessels from existing microvessels is angiogenesis, an histological
indicator of the degree of malignancy and prognosis of patients. Of all solid tumors, malignant
brain tumors show the highest degree of vascular proliferation. The WHO classification
distinguishes low grade from high grade diffuse astrocytomas by the presence of microvas‐
cular proliferation as a diagnostic criterion and an independent prognostic parameter [18].
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications210
HGGs are characterized by extensive microvascular proliferation and a higher degree of
vasculature. The presence of marked endothelial glomeruloid-like proliferations demonstrates
active tumor invasiveness through vascular angiogenesis, disruption of pre-existing anatom‐
ical structures and neoplastic cellular migration along neoangiogenic vascular channel and
through the BM, with evidence of proliferation of new fine capillaries [8, 19]. These mecha‐
nisms demonstrate a very strong and bidirectional correlation between glioma angiogenesis
and invasiveness into glioma progression. The new vessel growth is stimulated through the
tumor cells secretion of pro-angiogenic growth factors; these factors bind to receptors on
endothelial cells thereby activating them [20].
Vascular endothelial growth factor-A (VEGF-A) is regulated in HGGs and it is secreted by
tumor cells as well as by stromal and inflammatory cells. VEGF-A can be linked in the ECM
through the interaction with proteoglycans or glycosaminoglycans. The expression of the
receptors VEGFR1 and VEGFR2 is regulated on the endothelial cells in HGGs. The ligands for
VEGF3 (VEGF-C&D) are expressed by multiple cell types that surround the angiogenic vessels,
suggesting the existence of a novel pro-angiogenic paracrine signaling pathways in these
neoplasms [10, 21]. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and,
focally, by the tumor cells too. The receptors for bFGF include FGFR1, expressed by both the
tumor cells and the tumor endothelial cells; FGFR2 is expressed only by the tumor cells whereas
FGFR4 is not detected in HGGs [22]. The binding of VEGF on endothelial cells activates the
phosphatidylinositol-3-hydroxyl kinase (PI3K)/protein kinase B (Akt) pathway, whereas the
bFGF receptors are predominantly shown through the protein kinase Cα (PKCα) pathway.
The activation of endothelial cells results in increased expression of cell adhesion receptors,
such as integrins ανβ3 and α5β1, and in increased cell survival, proliferation and migration
responses. Other pro-angiogenic growth factors, including interleukin-8, hepatocyte growth
factor, urokinase can promote or amplify angiogenesis.
Cancer angiogenesis is similar to angiogenesis seen during development except that it is less
controlled and precise [23]. These blood vessels have many marked features including blind
ends, erratic size and connections, and most significantly, large gaps in the endothelial lining.
This last feature is important because it signifies that larger molecules can enter the tumor
effectively bypassing the blood brain barrier. In fact, tumor vasculature can have intercellular
gaps as large as 2 μm which is large enough for passive accumulation of 100-200nm particles
into the tumor interstitium [24]. Neovascularization in brain tumors correlates directly with
their biological aggressiveness, degree of malignancy and clinical recurrence and inversely
with the post-operative survival of patients with gliomas. Diffuse astrocytomas tend to
progress from grade II to grade III tumors with a time interval of several years, whereas,
progression of grade III to grade IV is more rapid, typically 2 years. GBMs that arise from a
low-grade glioma lesion are called “secondary glioblastoma”.
However, in most cases, GBMs appear “de novo” and are thus termed “primary glioblastoma”.
Regardless of their mode of progression, primary and secondary GBMs are morphologically
indistinguishable and show their histologic hallmarks, such as “glomeruloid” microvascular
tufts and necrosis [25, 26].
From Gliomagenesis to Multimodal Therapeutic Approaches into High-Grade Glioma Treatment
http://dx.doi.org/10.5772/52782
211
The discovery of hypoxia inducible factor-1 (HIF-1) and the observation that hypoxia-induced
HIF-1α expression in pseudopalisading cells, into intratumoral necrotic areas, was concomi‐
tant with the expression of one of its target genes, VEGF, established a biological link between
hypoxia and angiogenesis [27]. The formation of new blood vessels occurs physiologically
during embryogenesis. In adult life it is observed in the female reproductive system and during
wound healing and in a wide range of pathologic settings, such as ischemic diseases, chronic
inflammatory reactions, and neoplasia. During embryonic development, blood vessels are
newly formed from endothelial precursors and hematopoietic stem cells, a process known as
vasculogenesis [28]. In contrast, angiogenesis, the sprouting of new blood vessels from pre-
existing ones results from an altered balance of proangiogenic factors and antiangiogenic
factors [29, 10].
The sequence of events leading to the formation of new blood vessels is well characterized and
involves an initial VEGF-mediated increase of vascular permeability leading to extravasation
of plasma proteins associated with dilatation of native vessels and reduction in their pericyte
coverage. Subsequently, endothelial cells migrate and proliferate. For this cascade to occur,
deposition of a proangiogenic matrix for the newly sprouting vessel is essential. This involves
breakdown of the vascular basement membrane and extracellular matrix (ECM) through the
action of cathepsin B, matrix metalloproteases (MMPs) and other enzymes as well as the
expression of matrix proteins such as fibronectin, laminin, tenascin-C and vitronectin. Finally,
the angiogenic process culminates in the assembly of endothelial cells to form a vascular lumen
followed by the elaboration of a new basement membrane and the recruitment of pericytes. In
contrast to the accepted dogma that tumor development occurs in 2 phases (avascular and
vascular), we observed that tumor growth in the brain follows 2 vascular phases. In the first
vascular phase, the vessels are native cerebral vessels, which are coopted by tumor cells, while
in the second phase, there is true neovascularization arising from existing vessels. During the
transition period between these two phases, hypoxia driven HIF-1 expression occurs which
results in VEGF secretion and induction of neovascularization. In Stage IV, angiogenesis
adjacent to the necrotic area is triggered in response to increased expression of HIF-1α and
VEGF, a process that rescues the remaining tumor cells. Thus, it is possible to suggests four
sequential steps in glioma progression: i) perivascular organization, ii) proliferation, iii)
vascular regression followed by necrosis, and iv) angiogenesis.
Glioma vasculature is structurally and functionally abnormal and it correlates and leads to
vasogenic edema, increased interstitial pressure, and eterogeneous delivery of oxygen and
drugs [23].
VEGF expression is stimulated by hypoxia and acidosis, and probably correlates with many
other growth factors and their specific receptors (EGFR, HGFR, PDGFR, C-Kit, IGFR), and
downstream signaling pathways (PI3K-Akt, Ras-MAPK) upregulation and activation in
gliomas.
Many other proangiogenic factors are upregulated in gliomas and this aspect might explain
the failure of many actual antiangiogenic therapeutic strategies in gliomas management.
Among these other angiogenic factors a very important role has absolved by bFGF, IL-1beta,
IL-6, IL-8, TNF-alpha and stromal-cell-derived factor (SDF)-1 alpha [2].
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Another group of endothelial growth factors is represented by angiopoietins. Their signal
transduction pathway passes via the Tie2 receptor tyrosine kinase expressed on endothe‐
lial cells. In particular, Ang-1 and -2, have been implicated in glioma angiogenesis. Ang-1
mediated activation of  Tie2  is  required for  stabilization,  remodelling and maturation of
blood  vessels,  promotes  angiogenesis  and  tumor  growth  and  is  associated  with  an  in‐
creased number of highly branched vessels covered by pericytes. While VEGF and Ang-1
may act in concert (proliferation and maturation), Ang-2 has been implicated in further re‐
modeling of the initial microvasculature [30, 31]. Increased expression of Ang-2 on GBM
microvasculature appears early during glioma angiogenesis.  However,  binding of Ang-2
to the Tie2 receptor on endothelial cells antagonizes this receptor’s phosphorylation, there‐
by disrupting contacts  between endothelial  and periendothelial  support  cells  and disen‐
gaging  pericytes  from  the  tumor  vessels  during  initiation  of  vessel  sprouting  or
regression.  Examination  of  the  expression  patterns  of  angiopoietins  and  their  receptors
suggests a role in GBM vasculature and malignant transformation. For example, increased
Tie2  expression  has  been  observed  with  increasing  human  astrocytoma  grading.  Ang-2
and Tie2 expression are absent in the normal brain vasculature but are induced in tumor
endothelium of coopted tumor vessels prior to their regression. Of particular importance,
treatment of glioma cell derived mouse xenografts with a dominant negative form of Tie2
results in a significant decrease in tumor growth [32].
A new more complex understatement of angiogenic pathways in glioma progression gives a
crucial role to the Ca2+ permeable transient receptor potential (TRPC) channels in tumor
angiogenesis, and in particular in endothelial permeability up-regulation, focal adhesion
assembly, cell orientation and directional migration and involvement in hypoxia-induced
angiogenesis and vascular remodeling. According this complex molecular pathological
network, tumor angiogenesis should be not only the result of physiological adaptation to
hypoxia in response to an increasing tumor mass but it should be also the result of critical
genetic mutations that activate a transcriptional program for angiogenesis. Calcium (Ca2+) is
an important second messenger and its entry through plasma membrane affects angiogenesis.
Several reports indicate that Ca2+ permeable transient receptor potential (TRP) channels
belonging to the TRPC, TRPV and TRPM represent target genes, down-stream to Notch1,
PTEN, NFAT and Hif-1 transcriptional factors are activated during tumor angiogenesis.
Several studies indicate that angiogenic growth factors such as vascular endothelial growth
factor (VEGF) and basic firoblast growth factor (bFGF) may activate TRP channels at tran‐
scriptional and post-transcriptional levels, causing a subsequent rise in endothelial [Ca2+]i,
which modulates signal transduction pathways regulating the angiogenesis. Conversely, Ca2+
influx through TRP channel activation may stimulate endothelial cells to trigger transcription,
production and release of angiogenic growth factors such as VEGF and platelet-derived
growth factor (PDGF) that stimulate angiogenesis.
In the field of new targeted-based molecular therapeutic approaches, TRP channels, and not
only VEGF/VEGFR and HIF-1alpha, might be a promising target for new therapeutic agents
to anti-angiogenic therapy [33].
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4. Current treatment of glioblastoma
The efficacy of current anti-cancer multimodal therapeutic strategies in gliomas is limited by
the lack of specific therapies against malignant cells, and the prognosis in patients affected by
primary brain tumors is still very unfavorable. Glial tumors seem to be able to create a favorable
environment for the invasion of neoplastic cells when they combine with the extracellular
matrix via cell surface receptors, through the upregulation of crucial pathways such as
angiogenesis and invasion. The major problem in brain drug delivery is the presence of the
blood brain barrier which limits the delivery of many chemotherapeutic agents and other kinds
of therapeutic molecules. This event often contributes to the failure of treatment. Current
treatment of glioblastoma (GBM) is difficult and a great mysterious challenge, and, results in
high recurrence rates. Upon display of symptoms of a brain tumor (seizure, chronic headache,
loss of consciousness, loss of motor/sensory function) a patient will undergo MRI for detection
of the tumor. This is followed by a host of treatments to remove the bulk of the tumor if possible,
starting always when possible from gross total removal of tumor [34]. Patients are then
monitored for recurrence. This is standard protocol for treatment of glioma regardless of grade
[35]. This line of treatment can often lead to decreased quality of life. Last, if tumor recurs,
there are last line treatments given after which there is no ability to treat further. The treatment
of glioma is varied depending on grade, but this discussion will focus on the treatment of the
most aggressive form: glioblastoma (GBM). The common treatment after detection has several
components including: 1. Surgical resection of tumor from the primary site, 2. Lining of the
primary site with carmustine wafers designed to kill cells in the close proximity, after gross
total removal and histological confirmation of high-grade gliomas 3. Metronomic oral
temozolmide chemotherapy and 4. Radiotherapy to the brain. As mentioned previously, in
the case of recurrence, this treatment is coupled with anti-angiogenic therapy to prolong
patients’ life.
5. Surgical resection
Represents the microneurosurgical removal of the tumor from the primary site. The general
procedure involves craniotomy followed by suction and gross total removal of tumor from the
site. Though there are experimental imaging agents, such as optically visible fluorescent dyes
coupled with intravital magnetic resonance imaging of the brain for guidance and assessment
of accuracy and completion, this is not an exact science [35-37].
6. Local, intracavitary, chemotherapy
It is applied in the resection site after removal of the tumor gross in the form of Poly (lactic-
co-glycolic acid)-BCNU wafers that slowly degrade and release the chemotherapeutic BCNU
(Carmustine - gliadel®) into the resection site, after extemporaneous histological intra-
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operatory examination and confirmation of high-grade gliomas [38]. This local chemothera‐
peutic approach has been reported to yield a slight increase in survival times, as opposed to
leaving the tumor site empty, however, it still does not allow adequate decrease in recurrence.
Use of gliadel® has become less common place due to both cost-benefit analysis and preference
of use by surgeons [39, 40].
7. Radiotherapy and stereotactic radiosurgery
It involves the use of gamma-irradiation in order to induce cell death through DNA damage,
often inside a post-operatory adjuvant therapy. The technologic support to apply this thera‐
peutic step does see the use of Gamma-knife, cyber-knife or conformational collimation
system-based linear accelerator. This therapy is used in over 50% of all cancer patients at some
point during treatment and has been in use in cancer for almost a century. In brain tumors,
this treatment works by sending gamma rays through to the site of the tumor to directly
damage DNA, but in longer-lasting effects, creates free radicals which can go on to cause
further damage [41, 42]. Radiation therapy involves not just radiation of the tumor, as would
be desirable, but irradiation of an area which can include both tumor tissue and healthy brain
tissue. Radiotherapy does usually results in death of large amounts of the tumor, however,
recent discoveries suggest that radiation may actually be causing side effects which can aid in
recurrence. Glioma cells exposed to radiation in vitro show increased invasion post treatment,
indicating progression and enhanced malignancy of disease [43]. Further, radiation leads to
many side effects associated with cancer malignancy and disease progression, including the
creation of free radical species, degradation of the extracellular matrix, inflammation and
immune cells recruitment, and increased blood flow to the tumor area [44, 45].
Radiotherapy improved several clinical end points in brain tumors. Standard radiation therapy
of gliomas involves the provision of 59.4 / 60 Gy, in 30/33 from 1.8 to 2 Gy daily fractions, and
each should begin within 4-6 weeks after surgery. Treatment is generally given to the area of
the tumor and a surrounding margin (“limited-field” method). Postoperative radiotherapy
significantly prolongs median survival to approximately 12 months for glioblastoma multi‐
forme and to 36 months for anaplastic astrocytoma [46]. A slight improvement of the results
obtained with conventional radiotherapy has been achieved through the hyperfractionation
daily, the use of radiosensitizers or hyperoxygenation by hyperbaric treatment [47].
Stereotactic radiotherapy is helpful for the treatment of high grade gliomas and involves the
local system of radioactive sources (interstitial brachytherapy) or external targeted radiother‐
apy. In case of tumors of a limited volume boost stereotactic radiotherapy, administered by
linear accelerator or Gamma-Knife or Cyber-knife and performed after limited-field radio‐
therapy, achieved a slight increase in survival in some studies [48].
The metabolic radioimmunotherapy, using radiolabeled antibodies injected systemically or
intramuscularly, is still experimental because there are no phase III trials that showed a
survival advantage [49].
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8. Systemic chemotherapy
At present there is not a standard treatment of anaplastic oligoastrocytoma and oligodendro‐
glioma but the common practice, based on recommendations of the National Comprehensive
Cancer Network (NCCN), consists in surgery followed by radiation therapy. Adjuvant
chemotherapy can also be administered and consists in PCV or TMZ.
Loss of heterozygosity (LOH) of chromosome 1p/19q (present in approximately 40-60% of
oligodendroglial tumors) has been showed to be related to the sensitivity to the treatment with
alkylating agents (especially TMZ and poli-chemotherapy scheme PVC) and to a more
favorable prognosis. For a most appropriate therapy would therefore be necessary to look for
the loss of heterozygosity 1p and 19q in all tumors with oligodendroglial component [50].
Two clinical trials are evaluating the role of chemotherapy in the treatment of anaplastic glioma
correlating it to the co-deletion 1p/19q. The first, EORTC 26053-22054 is a Phase III trial on
concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic
glioma. The second is EORTC 26081-22086 a Phase III intergroup study of radiotherapy versus
temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for
patients with 1p/19q codeleted anaplastic glioma.
Oligodendrogliomas and oligoastrocytomas, especially in anaplastic forms, are highly
sensitive to adjuvant chemotherapy with PCV after radiation therapy, with a significant
increase in progression-free survival (23 months vs. 13 months) compared to radiotherapy
alone. An increase of the progression-free survival is also reflected by administering the PCV
before radiotherapy. None prolongation of the median overall survival time is noted [51].
Nevertheless, there is the common practice of proposing chemotherapy as the initial therapy
for pure oligodendroglioma. Further, in the case of small tumors RT remains the best thera‐
peutic choice. Although there is no phase III clinical studies comparing PCV and TMZ in
clinical practice TMZ is preferred as first line treatment for the lower toxicity and comparable
efficacy to PCV. Second line chemotherapy with TMZ in recurrent oligodendroglial tumors
after PCV-chemotherapy gave excellent results, and similar responses to PCV but with less
toxicity [52].
Standard therapy of anaplastic astrocytoma, according to Stupp protocol, is radiotherapy
with adjuvant TMZ, administered for the duration of radiotherapy ( 75 mg/m2 daily) and
after in six cycles (150-200 mg/m2 for five days every 28 days). There are no randomized
studies with adequate statistical power in patients with anaplastic astrocytoma that demon‐
strated a benefit of adjuvant or concomitant chemotherapy with nitrosoureas. In a EORTC
study, comparing adjuvant dibromodulcitol and BCNU chemotherapy with radiotherapy
alone in patients with anaplastic astrocytoma, no statistically significant improvement in
survival was observed after BCNU/DBD adjuvant chemotherapy [53].  Temozolomide, an
imidazotetrazinone acting through the formation of a reactive methyldiazonium cation and
methylation of O6-guanine in DNA, induce its clinical effects through the activity of O6-al‐
kylguanine-DNA alkyltransferase (AGT), a DNA repair protein that removes O6-alkylgua‐
nine adducts in DNA, result of translation from gene MGMT, whose grade of promoter
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methylation is  recognized important  epigenetic  predictive factor  to  temozolomide thera‐
peutic response. The therapeutic advantage is showed for patients with MGMT (methyl‐
guanine methyltransferase) methylated tumors. The enzyme remove alkyl groups from the
O6 position of guanine, one of the targets of alkylating agents. Epigenetic silencing of the
MGMT gene in tumor tissue occurs through the methylation of the CpG islands in the pro‐
moter region. Patients whose tumors have MGMT promoter methylation are likely to bene‐
fit from the addition of TMZ chemotherapy [54]. TMZ is characterized from an excellent
oral bioavailability and good penetration of the blood-brain barrier (BBB). The activity of
temozolomide is highly dependent on dosing schedule, with multiple administrations be‐
ing more effective than a single dose (as normally codified in Stupp protocol). Peak plasma
concentration is achieved within 30-60 min of oral administration and the compound has
an elimination half-life of one to two hours. Myelosuppression, which is dose limiting at
1,200 mg/m2, and nausea and vomiting are the most frequent adverse events [55].
A new promising agent, recently evaluated for the treatment of anaplastic astrocytoma, is
Trabedersen, a phosphorothioate antisense oligonucleotide that act as an inhibitor of TGF- β2
(Transforming growth factor-beta 2) biosintesys. TGF- β2 levels seems to be higher in high
grade gliomas. TGF-β2 is an attractive target because it regulates key mechanisms of carcino‐
genesis, in particular immunosuppression and metastasis. The compound was tested in phase
I/II studies, in which it was administered at two doses (10 μM or 80 μM) comparing response
rate, survival, and safety respect to standard chemotherapy (TMZ or PCV). Trabedersen 10
μmol/L was superior to trabedersen 80 μmol/L in both efficacy and safety for high-grade
gliomas, especially in anaplastic astrocytoma. In patients with anaplastic astrocytoma, the
trabedersen 10 μmol/L group had a higher overall survival rate at 24 months than the trabe‐
dersen 80 μmol/L group and the control group (83.3%, 53.3% and 41.7%, respectively). The
median overall survival for patients with anaplastic astrocytoma was higher in both trabe‐
dersen groups than in the chemotherapy control group, with a survival benefit for 10 μmol/L
trabedersen over chemotherapy (17.4 months). Based on the promising results of these studies,
presented at the 101st annual meeting of American Association of Cancer Research, in 2010
started the pivotal Phase III study SAPPHIRE (Efficacy and Safety of AP 12009 in Adult Patients
With Recurrent or Refractory Anaplastic Astrocytoma [WHO Grade 3) as Compared to
Standard Treatment with Temozolomide or BCNU: A Randomized, Actively Controlled, Open
label Clinical Phase 3 Study). Unfortunately, the study has been stopped prematurely in
January 2012, due to slow patient recruitment [56].
Historically, the standard of care for older adult with GBM was surgical resection or biopsy,
followed by involved-field radiotherapy. The new therapeutic standard is based on the results
of several studies that demonstrated a significant survival benefit in GBM patients with the
addition of concurrent and adjuvant TMZ to radiation. Patients treated with TMZ/RT had a
median survival time of 15 months, compared with 12 months for the patients initially treated
with RT alone. Further, the first group showed a 2-year survival rate of 26% compared with
only 10% for the RT group. Now the standard treatment consist in surgery followed by RT
with adjuvant TMZ, administered for the duration of radiotherapy and after in six cycles
(Stupp protocol) [57].
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A therapeutic alternative or adjunctive treatment is BCNU wafer (Gliadel®), positioned at sur‐
gery and followed by radiation therapy. Gliadel® is a biodegradable polymer wafer impregnat‐
ed with BCNU. At the time of resection, up to eight wafers are implanted into the surgical cavity.
Water in the interstitial fluid causes the polymer slowly to degrade. The BCNU is thus released
in a controlled manner over several days to weeks and diffuses into the brain parenchyma at a
high dose density. It causes a statistically significant increase in survival compared to patients
treated only with surgery and radiotherapy. The SIGMA (Stupp including Gliadel for glioma) is
a multi-center, spontaneous observational trial to evaluate the efficacy of Gliadel® wafers plus
concomitant TMZ in patients with newly-diagnosed high grade glioma. This study is conduct‐
ed at the Foundation of the Carlo Besta Neurological Institute, IRCCS, in Milan and is based on
several examples in literature on this association. Samaggi et al. of the IRCCS published a study
on the research and comparison of data in literature about efficacy and toxicity in patients with
newly diagnosed GBM treated with the combination of Gliadel® and the Stupp protocol. Anal‐
ysis of data revealed that this combination is well tolerated and it significantly improved sur‐
vival without a substantial increase in toxicity [58].
Recently was demonstrated that for elderly patients with newly diagnosed glioblastoma,
therapy with TMZ alone is an alternative to radiotherapy. In the study, published in the July
issue of the Lancet Oncology, were recruited 412 older patients. 195 were randomly assigned
to TMZ and 178 to radiotherapy. The results showed that single-agent TMZ and radiotherapy
alone seem equally effective. Both treatments were well tolerated. Major side effects observed
were neutropenia, (16 in the TMZ group and 2 in the RT group), lymphocytopenia (46 vs. 1),
thrombocytopenia (14 vs. 4), hepatic enzyme increased (30 vs. 16), infections (35 vs. 23) and
thromboembolic events (24 vs. 8). Even in older patients the MGMT methylation status of
tumor is a predictive marker for the success of therapy with alkylating agents as mentioned
above. So testing of tumor MGMT methylation status in elderly patients with newly diagnosed
glioblastoma should be a priority to decide the best treatment [59].
9. Antiangiogenic therapy
Angiogenesis inhibition represents a new target for therapeutic intervention in malignant
gliomas because GBMs are highly vascularized brain tumors and their growth seems to be
angiogenesis dependent.
The inhibition of angiogenesis is achieved through the use of inhibitors of VEGF receptor (such
as bevacizumab or aflibercept) or kinase or integrin inhibitors (cilengitide or erlotinib) which
have been tested in several clinical trials.
The antiangiogenic effect is achieved through different mechanisms assumed on the basis of re‐
sults from several studies. According to the first hypothesis (starvation hypothesis), the reduc‐
tion of new blood vessels formation decreases the amount of metabolites that may reach the
tumor, causing tumor cell death. According to a new hypothesis (normalization hypothesis), in
the early stages (1 month) of the antiangiogenic therapy there is a normalization of the blood
vessels, followed by their damage due to hypoxia, and then by the reduction of tumor growth.
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These hypothesis have been confirmed by recent studies in which was highlighted the increase
of metabolites associated with anaerobic glycolysis in the long-term therapy with anti-VEGF.
This would explain the failures obtained in the treatment of solid tumors with anti-VEGF
monotherapy but also the excellent results of several trials with the association anti-angiogenic
agent and chemotherapy, even compared to chemotherapy alone [60].
The need to associate an antiangiogenic agent to traditional therapy is useful not only to
improve the vehiculation of the anticancer drug but also to control recurrences. According to
clinical experience, after surgical resection, radiotherapy and adjuvant chemotherapy with
TMZ, there is a recurrence or progression within six months. This recurrence is localized in
most cases where there was the resection of the primary tumor, in which are localized tumor
cells infiltrated. This phenomenon has been explained assuming that the primary tumor
secretes not only pro-angiogenic agents but also anti-angiogenic agents that inhibit neovas‐
cularization at the level of infiltrating tumor cells, which are located at a certain distance from
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the primary tumor. For this reason the use of anti-angiogenic agents is recommended not only
in newly diagnosed gliomas but also in recurrences [61].
10. Anti VEGFR — Bevacizumab
Bevacizumab (Avastin®;Genentech, CA, USA) is a recombinant humanized monoclonal
antibody that binds with high affinity to human VEGF preventing it from binding to its
receptors VEGFR1 and VEGFR2, on the surface of endothelial cells and thereby determining
the block of the cascade of events following its receptors activation. Will be therefore inhibited
proliferation and increased permeability due to receptor VEGFR2 and tumor growth due to
receptor VEGFR1 through the production of matrix metalloproteinases. Bevacizumab inhibits
the growth of new blood vessels and reduces the blood flow to the tumor. Like other antian‐
giogenic agents it shows, in the initial phase of the treatment, a normalizing effect on blood
vessels. This normalizing effect is important because tumor vasculature is often incomplete
and tends to leak. The abnormal permeability may prevent the administration of cancer
treatment such as chemotherapy. Bevacizumab can normalize the chaotic vascularization of
the tumor, in order to maximize the effectiveness of the overall therapeutic strategy.
In the U.S., Avastin® is the first anti-angiogenesis therapy approved by Food and Drug
Administration (FDA) to treat patients with glioblastoma multiforme (GBM) when this form
of brain cancer continues to progress following standard therapy. The drug is also approved
for the treatment of advanced stages of other 3 types of cancer: breast, colorectal, and non small
cell lung cancer (NSCLC). Even before FDA approval, bevacizumab was widely used for this
indication in the United States and in some European countries [62].
Many clinical trials evaluated efficacy of bevacizumab and irinotecan versus bevacizumab
alone (and the addition of irinotecan at progression) with several results but also with many
questions unanswered about the end points used, the increase in survival, the best dose and
timing. Teri N. Kreisl et al. conducted a trial to evaluate single-agent activity of bevacizumab
in patients with recurrent glioblastoma. The dose of bevacizumab was 10 mg/kg every 2 weeks.
At tumor progression bevacizumab was associated in combination with irinotecan 340
mg/m2 or 12 mg/m2 every two weeks. The study found that single-agent bevacizumab has a
significant antitumor effect in recurrent glioblastoma and show less overall toxicity but also a
lower response rates (29% vs. 46%) compared with combination therapy. The study shows that
it is not always strictly necessary the addition of irinotecan after tumor progression during the
treatment with bevacizumab. It is not possible, however, exclude the contribution of irinotecan
if the two agents are used together in the initial treatment. Will be necessary to conduct further
studies to understand whether the addition of this drug is so useful to offset the toxic effects
associated with its use [63].
Results from this trial are consistent with data presented by Vrendenburgh et al. emerged from
a phase II trial testing bevacizumab plus irinotecan in recurrent GBM. They reported a response
rate of 57% and a 6-month progression-free survival of 46% with this combination. The
rationale of combining the two drug is based on the normalization effect of antiangiogenic
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agents that reduce the intratumoral pressure and increase drug delivery to tumor. But there
could be also another unwanted effect, the reduction of drug penetration to the brain due to
the restoring of the blood-brain barrier [64].
Avastin® is approved in Europe for the treatment of advanced stages of four types of cancer:
colorectal cancer, breast cancer, lung cancer and kidney cancer. Together, these four types of
cancer cause nearly 3 million deaths every year. The use of the drug in Italy for malignant
gliomas is possible through the enrollment in clinical trials or the compassionate use. Com‐
passionate use programs are intended to facilitate the availability to patients of new treatment
options under development. National compassionate use programs, making medicinal
products available either on a named patient basis or to cohorts of patients, are governed by
individual Member States legislation. In Italy the global compassionate use is ruled by the
Ministerial Decree dated 8th May 2003. Drugs under experimentation may be used outside the
experimentation if there isn’t a valid therapeutic alternative [65].
The neuro-oncology department of Besta Institute is conducting a study on the therapeutic use
of bevacizumab and irinotecan in patients with recurrent grade III and IV glioma in the absence
of therapeutic alternative since is emerged by various studies the effectiveness of this associ‐
ation [66]. However, not all patients respond to bevacizumab-irinotecan combination. This is
probably due to the different pathways involved in tumor angiogenesis, in which VEGF is
only one factor, even though prevalent. The lack of response in some patients may be related
to any of the alternative routes [67].
Despite their contribution in the treatment of vascularized GBM, these agents have some
serious side effects including hypertension. For this reason, this therapy is a problem for
patients with underlying hypertension. In such cases is possible to associate calcium channel
blockers or ACE inhibitors to cancer therapy. ACE inhibitors are often preferred because in
hypertension caused by VEGF inhibitors the way of NO is involved, and it can be blocked by
these antihypertensive agents. Another side effect caused by the antiangiogenic therapy is
proteinuria, which can be prevented by these agents. The bevacizumab-irinotecan combination
is responsible for serious side effects such as renal failure and gastric perforation, which in
some cases lead to discontinuation of treatment. It is recommended that bevacizumab not be
initiated for at least 28 days after surgery and until any surgical wound is fully healed and that
bevacizumab be discontinued at least 28 days prior to elective surgery [62].
11. Integrin inhibitors — CILENGITIDE
Integrins are a family of transmembrane receptors whose natural ligands are represented
by vibronectin, fibronectin, laminin. Their ligands are recognized by the common portion
arg-gly-asp (RGD); upon binding occurs a conformational change, the formation of clusters
of integrins and the activation of intracellular kinases, from which depend many intracellu‐
lar signal cascades. These cascades result in the processes of proliferation, differentiation,
motility, survival and cell adhesion. Some integrins are ubiquitous, others are specific for
various tissues and are also expressed on the surface of different types of tumors. In such
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cases there will be an increase in the levels of both integrins in tumor cells than in endothe‐
lial cells in the proliferation phase during angiogenesis. Integrins most expressed are αvβ3
and αvβ5. Using these integrins as targets, will be therefore possible to obtain an antiangio‐
genic and anticancer effect.
There are several types of integrine inhibitors that have been evaluated in preclinical and in
clinical trials: peptidomimetics (Cilengitide), antibodies (Intetumumab, Natalizumab), small
organic molecules (E7820- MK0429]). The advantage of small organic molecules compared to
previous compounds lies in greater stability and in oral administration instead of intravenous.
Cilengitide (developed by Merck KGaA) is a new anti-angiogenic agent for the treatment of
recurrent gliomas that act as an inhibitor of integrin receptors αvβ3 and αvβ5, expressed on
activated endothelial cells during angiogenesis. Integrins are proteins that facilitate the
formation of new blood vessels within the tumor; blocking the receptor binding leads to the
inability to invade the brain by the glioblastoma cells. This antitumoral and antiangiogenic
effect of Cilengitide was demonstrated by several preclinical studies [68]. The molecule, in a
phase II study presented at the American Society of Clinical Oncology (ASCO) in Chicago, was
tested at two different doses (2 g or 500 mg twice a week) and provided very promising results
in the group treated with the higher dose. Surprisingly, more than one third of patients in this
group was still alive after one year and 22% after 2 years. 10% were still alive after 4 years [69].
Stupp et al. conducted a Phase I/IIa study of cilengitide and TMZ with concomitant radio‐
therapy followed by cilengitide and TMZ maintenance therapy in patients with newly
diagnosed glioblastoma. Cilengitide at 500mg was administered as a 1-hour intravenous
infusion twice weekly. The study highlighted how treatment with cilengitide, combined with
the standard treatment, showed benefits in patients with MGMT promoter methylation.
MGMT gene promoter methylation status was determined by methylation-specific polymer‐
ase chain reaction (PCR). The combination of cilengitide with TMZ and radiotherapy was well
tolerated, without other side effects [70].
Merck is currently conducting two trials; the CORE study (cilengitide at a dose of 2 g twice
weekly in combination with TMZ and radiotherapy) is a Phase II randomized, multicenter,
open-label controlled trial investigating two regimens of intravenous cilengitide in combi‐
nation with standard therapy (radiotherapy with concurrent  and adjuvant  TMZ) versus
standard therapy alone, and is currently in progress in GBM patients with an unmethylat‐
ed MGMT promoter.
The CENTRIC study is a multicenter, open-label, controlled phase III study, testing Cilengitide
(at a dose of 2 g twice weekly) in combination with standard treatment (with TMZ and
radiotherapy ) versus standard treatment alone, in subjects with newly diagnosed glioblasto‐
ma multiforme and methylated MGMT gene promoter. Promising results in these trials
probably will lead to a higher interest in integrins as targets for glioma therapy and to a bigger
development of new anti-integrin agents. The results of clinical studies will be useful to explore
the knowledge on the best dose of cilengitide used to obtain the desired therapeutic effect with
lower side effects.
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Recently the research of biomarkers predictive of patient response to anti-integrin agents has
been directed toward the quantification of their expression through imaging, using radiola‐
beled galacto-RGD positron emission tomography, a new diagnostic technique [68].
12. Antisense approaches and mi-RNA inhibitors as anti-angiogenic agents
New antiangiogenic agents have been developed and tested in several preclinical studies with
many results that encourage further research in this field. These are unconventional com‐
pounds such as siRNA and angiomirs which differently act through gene silencing. This
silencing mechanism has been used to interfere with the process of angiogenesis [61].
Other treatments to halt invasion involve genetic interventions using DNA, siRNA, and
microRNA delivery via a host of transfection methods [71]. These therapies are all in animal
phases at the moment, largely due to the invasive nature of the interventions and the difficul‐
ties in the past twenty years with gene therapy in clinical trials. The advantage of these
interventions is the ability to directly target specific genes necessary for glioma invasion
without need for design of a novel drug and determination of a particular target. However,
like all compounds, there are delivery issues associated with these treatments as well as
possible unforeseen side effects. Another kind of new possible antisense approach is repre‐
sented by long non coding RNA, different RNA-based molecules than miRNA, probably
transcripted not from intronic DNA sequences. All of these antisense approaches should be
reach to knockout or down-regulate pathways pathologically involved in glioma progression
and invasion, trying to reverse towards normality glioma cell genome or selectively kill only
glioma cells. Into this fashionable therapeutic field, our study group is improving the study of
possible involvement of IL-8 and HIF-1 alpha into high-grade glioma patients to hypothesize
an antisense block of both these molecules at the same time with a single approach.
13. Other potential molecular targets
Recent discoveries in molecular biology have shown further potential signaling pathways
involved in the pathogenesis of malignant gliomas. Were therefore assumed new targets
for novel  therapeutic  approaches like grow factor ligands,  receptors,  intracellular down‐
stream effectors. Several studies highlighted an over-expression of EGFR in malignant glio‐
mas, which is related with survival and proliferation of cancer cells. EGFR tyrosine kinase
inhibitors  (TKIs)  Gefitinib  (Iressa®)  and Erlotinib  (Tarceva®),  used in  combination with
ionizing radiation, can increase the antitumoral effect of this therapy. The results of several
phase I/II studies using Gefitinib and Erlotinib with conventional therapy in the treatment
of GBM are controversial [72]. For this matter were investigated other molecular markers
(besides the over-expression of EGFR) more predictive of EGFR TKIs activity. Among these
there  are:  EGFR  variant  III  (EGFRvIII  co-expressed  when  there  is  an  amplification  of
EGFR),  phosphatase  and  tensin  homolog  (PTEN)  expression,  and  phospho-Akt  (P-Akt).
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Specifically, co-expression of EGFRvIII and the tumor-suppressor protein PTEN seems to
be associated with a significant clinical response to EGFR TKIs but also these results are
controversial. Further studies are needed to clarify the efficacy of these agents and to select
patients who may benefit from EGFR inhibitor therapy. Imatinib (Glivec®), an antagonist
of PDGFR (who may be overexpressed in high grade gliomas), showed in vitro on GBM
cells cytostatic or cytotoxic activity in relation to its concentration [73]. This led to clinical
trials  in  patient  with  recurrent  glioma.  A randomized,  multicenter,  open-label  Phase  III
study of imatinib in combination with hydroxyurea versus hydoxyurea alone as oral thera‐
py in patients with progressive pretreated GBM resistant to standard dose TMZ failed to
show clinically significant differences between the two treatment arms [74].
Most experimental and more traditional anti-invasive therapeutic platforms have focused on
the ability of compounds to inhibit matrix metalloproteinases (MMPs) and the other extracel‐
lular matrix (ECM) components and thus limiting invasive progress of cancer cells [75].
One such compound, Marimastat, an MMP-2 inhibitor, was developed and showed promise
in some clinical trials, demonstrating a possible synergic effect when used with TMZ in
anaplastic astrocytoma and recurrent GBM. Despite it, actually, it isn’t sure a long term
therapeutic effect better than TMZ alone [76, 77]. More recently, there has been a shift in the
development of novel drugs to that of more personalized therapy. In these cases, specific
receptors and signaling molecules are targeted for inhibition in order to kill cancer cells. The
main goal to reach the selectivity and efficacy of antitumor treatment consist on targeted
therapeutic molecular-based approaches. These therapies in the field of brain tumor and in
particular in case of intra-assial brain tumor, such as high-grade gliomas, represent the most
fascinating challenge to achieve the killing of glioma cells into the brain and, with an adequate
engineering of targeted drugs and nanoparticles systems, the population of glioma and GBM
stem cells. Treatment can be modified to the individual cancer type and patient which is
advantageous in reducing side effects. They work often by relying on receptor addiction of the
cancer cells meaning if the receptor becomes useless through blocking, the cancer cell will
almost go through withdrawal and can die [78, 79]. However, this is not known to occur with
all potential targets and it is always possible that pathways will be rerouted to compensate.
This type of treatment often has a side effect of halting invasion of cancer cells though more
commonly treatment leads to cell death. A recent review highlights many of these compounds
and their potential anti-invasive effects based on the target molecule for which they were
developed. However, the exact anti-invasive effects are unknown for most of these compounds
based on lack of in depth studies of invasion opting instead for survival and tumor growth
measures. Most of the targets of this type of therapy are receptor tyrosine kinases (RTKs)
which, upon activation by a ligand, will change conformation and phosphorylate intracellular
signaling proteins leading to downstream events. In cancer, these receptors are often mutated
to be constituitively active and thus require no growth factors to function. A cancer cell can
actually become “addicted” to this activation and so by turning it off, the cell will die. Inhibitors
of RTKs are most often antibodies due to the high specificity. The more notable RTK inhibitors
are Herceptin® (against EGFR), Avastin® (against VEGF), and Tarceva® (against PDGFR).
These are all used clinically for different types of cancers and have been thought to have
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possible anti-invasive effects due to their signaling pathways involving targets for invasion
[80]. However, there is insufficient evidence to tie their effects to halting glioma invasion and
as aforementioned, in vivo, Avastin causes glioma invasion. EGFR inhibition is particularly
exciting due to the overexpression or mutation of EGFR in >60% of glioblastomas (de novo
GBM) and alteration of glioblastoma to express EGFRvIII causes a more invasive phenotype
of cells in vitro [81, 82]. However, these compounds are expensive and difficult to work with.
Further, their actual role in invasion prevention is yet to be seen due to the far-reaching effects
of the involved pathways.
Inhibitors of downstream proteins such as Src-kinase have shown promise in inhibiting tumor
growth and progression. Based on the ability of Src to increase the invasive phenotype
including cytoskeletal remodeling, MMP secretion, and adhesion disassembly, it was tested
for anti-invasive activity. This treatment inhibited invasion in brain, prostate and breast
cancers while also inhibiting growth, angiogenesis and proliferation [83].
Another new agent tested in clinical trials is Talampanel, a noncompetitive antagonist of the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. The receptor levels
may be related with the GBM growth. This compound was tested in a multicenter Phase II
study in association with standard therapy with RT and TMZ for newly diagnosed GBM.
Patients showed a median survival of 20.3 months and 2 year overall survival of 41.7%. Only
29% of patients had MGMT promoter methylated [72].
14. Conclusions and future perspectives
Based on the results obtained from both the old and the most innovative therapies seems clear
that a better understanding of the pathological and physiological mechanisms of brain cells
can result in a more targeted therapeutic approach by designing personalized therapies. This
would overcome the current limitations in the treatment and lead to a better prognosis for
patients with brain tumors.
Nowday, the treatment of gliomas represents one of the most challenging areas in neurosur‐
gery and oncology. Malignant gliomas involves multiple aberrant signaling pathways and the
BBB restricts the delivery of many chemotherapeutic agents. The efficectiveness of the actual
chemotherapeutic approach, multimodal targeted therapies, differently than the other
malignant extracerebral tumors, remains very modest in gliomas. Considering the multitude
of molecular entities and signaling pathways regulating the proliferation and cellular survival/
cell death, the inhibition of a singular target gene or transcriptional factor could not be
sufficient to suppress neoplastic progression. In this intricate and complex field it seems to be
very important to improve specific selective drug delivery systems to lead to diffusion of
drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibod‐
ies and other therapeutic molecules into CNS overcoming BBB.
Considering the multitude of actually used chemotherapeutic approaches, starting from Stupp
protocol (TMZ plus radiotherapy) and the results in term of recurrences and survival, the field
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of glioma therapy is again subject to high rate of investigation and development with the hope
to postulate new possible molecular targets and therapeutic schemes to attack glioma cells.
Understanding the genetic bases of gliomas and of the invasive behaviour, in particular the
differentiated gene expression in distinct areas of the same tumor during glioma progression,
may suggest new molecular targets to overcome the mechanisms of multi-drug-resistance of
the actual therapeutic approaches to gliomas and to attack at the same time different crucial
biological events of gliomagenesis.
Glioma gene expression and its development during gliomagenesis will may help to better
understand the role of important molecules involved in tumor-safe brain parenchyma
relationships. These molecules, such as ECM proteases, cell adhesion molecules and their
related signaling pathways show an important role in glioma cell migration and invasion and
could be selectively downregulated to inhibit the glioma invasive rim. It is clear that the
complexity and cross-talk between signal transduction pathways limits the potential efficacy
of targeting a single receptor or molecule.
We are now investigating the role of HIF (Hypoxic inducing factor) isoforms and IL-8
(Interleukine-8) in glioma progression and the possibility to block their pathways through a
only antisense molecule loaded into a nonaparticle-base system, and directed against both
these molecular targets. HIF-1α actively regulates downstream processes and it is also
influenced by the tumor microenviroment in many different ways. Antisense inhibition of HIF
may be a strong target for anti-angiogenic therapy. In fact, HIF is the crucial molecule and
transcriptional factor produced in response to hypoxic conditions within HIF-1α/VEGF-
regulation expression-dependent angiogenic pathway. In this molecular cascade HIF-1α up-
regulated levels finally induce up-regulation of VEGF expression, and, at the same time, may
stimulate gene expression of other genes involved in gliomagenesis.
Our group has recently demonstrated high expression levels of PGES-1 (Prostaglandine E 1
Sinthase) and IL-8 in HGG cells and microglial cells, strongly correlated with grading tumor.
During malignancy progression, leukocyte infiltration and necrosis are two biological
phenomena associated with the development of neovascularization. IL-8 expression is first
observed in low grade astrocytoma in perivascular tumor areas expressing inflammatory
cytokines. In HGGs, IL-8 further localizes in oxygen-deprived cells surrounding necrosis.
Macrophages are known to produce high levels of IL-8, which has a tumorigenic activity, by
inducing tumor growth and angiogenesis; IL-8 is an inflammatory chemoattractant respond‐
ing to the tumor microenvironment. Tumor pseudopalisading cells secrete hypoxic inducing
factor (HIF) which induces IL-8 secretion. On the base of our preliminary results, we hypothese
an important role of IL-8 as crucial angiogenesis mediator within HIF-1α pathway and
crosstalk between hypoxia-induced high levels of HIF-1α and VEGF expression. A simulta‐
neous selective antisense strategy against two molecular targets involved at different levels in
the same pathological pathway could be an attractive therapeutic mechanism aimed at
enhancing an anti-angiogenic and anti-tumoral effect.
A very interesting new field of research and therapeutic application in glioma treatment is
represented by studying and knowledge of differential phenotypic transcriptional profiles
expressed into gliomas, and GBM in particular. Hoelzinger et al. in their study have showed
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications226
two different gene expression profiles into two distinct subpopulations of glioma cells,
respectively the glioma cells located inside the stationary and proliferative tumor core and the
glioma cells, located inside the motile and invading tumor rim. The authors report two
different pattern of gene expression, characterized respectively by high levels of IGFBP2 and
vimentin into tumor core glioma cells and upregulated expression of genes involved in
adhesion, extracellular signal transduction, cytoskeletal rearrangement, intracellular signal
transduction and apoptosis. In particular genes upregulated in invasive cells are autotoxin
(ATX), the autocrin motility factor, protein tyrosine kinase 2 beta (PYK2), ephrin B3, antia‐
poptotic factor B-cell lymphoma-w (BCLW) and death-associated protein 3 (DAP3). The
existence of two different gene expression profiles into distinct areas of the same tumor
suggests the possibility to attack different molecular pathways and steps of glioma progression
at the same time, targeting selectively different subsets of glioma cells. This introduces the
possibility of multiagent treatment modalities, specifically targeting invasive cells, through
new molecular therapeutic approaches in conjuction with classic treatments [84].
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